...
首页> 外文期刊>The oncologist >Individualized Prediction of Survival Benefit from Postmastectomy Radiotherapy for Patients with Breast Cancer with One to Three Positive Axillary Lymph Nodes
【24h】

Individualized Prediction of Survival Benefit from Postmastectomy Radiotherapy for Patients with Breast Cancer with One to Three Positive Axillary Lymph Nodes

机译:乳腺癌患者的乳腺癌后疗法放射治疗的个性化预测患者用一中患有一至三个阳性腋窝淋巴结

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose There still exist some arguments regarding the use of postmastectomy radiotherapy (PMRT) for patients with breast cancer carrying one to three positive axillary lymph nodes considering the heterogeneity of this cohort. Here, we developed a prognostic nomogram to estimate the probability of long-term outcome in patients receiving or not receiving PMRT in order to assist in making individually locoregional treatment decisions for this particular cohort. Methods Altogether, 20,336 women, aged 18 to 80 years, diagnosed with breast cancer, and carrying one to three positive nodes were identified in the Surveillance, Epidemiology, and End Results (SEER) database. We applied multivariant Cox hazard model to determine the impact of covariates on disease-specific survival (DSS) and overall survival (OS). Then, the nomogram was built accordingly. Internal and external validations were performed to examine the accuracy of nomograms. Results Age of diagnosis, tumor grade, size, estrogen and progesterone receptor status, and number of positive nodes were independent factors of DSS and OS in the multivariate analysis. Incorporating these factors into the constructed nomogram showed high accuracy when predicting 5- and 10-year survival, with internally and externally bootstrap-corrected concordance indexes in the range of 0.6 to 0.8. Conclusion Besides the number of involved nodes, extra variables existed as predictors of survival outcomes in this cohort; therefore, the recommendation of PMRT or no PMRT requires comprehensive consideration. This clinically validated nomogram provided a useful tool that could aid decision making by estimating DSS and OS benefits from PMRT, useful in predicting 5- and 10-year DSS and OS for patients with one to three positive nodes after mastectomy. Implications for Practice This study evaluated population-based data to identify prognostic factors associated with patients with breast cancer with one to three lymph nodes and help clinicians to weigh the benefit of postmastectomy radiotherapy (PMRT). Surveillance, Epidemiology, and End Results (SEER) data were used to develop a prognostic nomogram to predict the likelihood of long-term survival with and without PMRT in order to optimize the individual locoregional control strategy for this particular cohort. This clinically validated nomogram provides a useful tool to predict 5- and 10-year disease-specific survival and overall survival for patients with one to three positive nodes and can aid tailored clinical decision making by estimating predicted benefit from PMRT.
机译:目的仍然存在关于使用乳腺癌患者的乳腺癌的患者患有乳腺癌的患者,考虑到这种队列的异质性。在这里,我们开发了一个预后的载体,以估计接受或未获得PMRT的患者的长期结果的可能性,以协助为此特定的队列制定单独的习俗治疗决策。方法中,患有乳腺癌的20,336名女性,患者18至80岁,并在监测,流行病学和最终结果(SEER)数据库中鉴定了患有乳腺癌的18至80岁,并携带一到三个阳性节点。我们应用多变量Cox危险模型,以确定协变量对特异性生存(DSS)和总存活(OS)的影响。然后,载体建立了相应的构建。进行内部和外部验证以检查载体的准确性。结果诊断年龄,肿瘤等级,大小,雌激素和孕激素受体状态,以及阳性节点的数量是多元分析中DSS和OS的独立因素。将这些因素纳入构建的墨迹图表,在预测5年和10年的生存时,在内部和外部引导校正的一致性指数在0.6至0.8的范围内显示出高精度。结论除了涉及节点的数量,额外的变量存在于此队列中生存结果的预测因子;因此,PMRT或未审议PMRT的建议需要全面考虑。该临床验证的NOM图提供了一种有用的工具,可以通过估计PMRT的DSS和OS益处来帮助决策,用于预测乳房切除术后一至三个阳性节点的5岁和10年的DSS和OS。对实践的影响本研究评估了基于人群的数据,以鉴定与乳腺癌患者的预后因素,患有乳腺癌一至三个淋巴结的患者,并帮助临床医生权衡后切除放射治疗(PMRT)的益处。监测,流行病学和最终结果(SEER)数据用于开发预后的载体图表,以预测与PMRT的长期生存的可能性,以优化这种特殊队列的个别习惯控制策略。该临床验证的墨迹提供了一种有用的工具,可预测一至三个阳性节点的患者的5年和10年的疾病特异性生存和整体存活,并通过估计从PMRT预测的益处来帮助量身定制的临床决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号